Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development
February 04 2020 - 7:02AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on developing
and commercializing innovative therapies for people with rare
debilitating, chronic neuromuscular and neurological diseases,
today announced the appointment of David Ailinger as Vice
President, Business Development, reporting directly to Patrick J.
McEnany, Catalyst’s Chairman and CEO. Mr. Ailinger will be
responsible for leading the Company’s business development and
corporate strategy initiatives, including licensing and partnering
discussions.
“We are delighted to add David to our senior
management team at such a transformative time for our Company,”
said Mr. McEnany. “Dave is a seasoned veteran with 15 years of
business development experience with branded drugs. He brings
valuable new skills to Catalyst at a time when business development
is a core strategic focus for us, as we look to broaden our
portfolio of commercial products, our pipeline of late-stage
development programs, and our global footprint.”
“I am excited to join Catalyst as the Company continues to make
an impact for those suffering from rare diseases,” said David
Ailinger. “I look forward to working with the Catalyst team as we
seek to grow our business and bring innovative therapies to
patients worldwide.”
Mr. Ailinger most recently served as Senior Director of
Corporate Development at Impax Laboratories, where he was
responsible for business development activities for specialty
products, including the identification, evaluation, negotiation and
execution of business development activities. Prior to joining
Impax, Mr. Ailinger was Executive Director of global business
development at Actavis (formerly Watson Pharmaceuticals). At
Actavis, he was responsible for leading global brand business
development initiatives. Prior to joining Actavis, Mr. Ailinger was
a director of business development and licensing at Teva
Pharmaceuticals, previously Barr Laboratories, where he performed a
series of roles in corporate and business development across
multiple therapeutic areas.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia
gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3.
Catalyst's new drug application for Firdapse® (amifampridine) 10 mg
tablets for the treatment of adults with LEMS was approved in
November 2018 by the U.S. Food & Drug
Administration ("FDA"), and Firdapse is now commercially
available in the United States. Prior to its approval,
Firdapse for LEMS had received breakthrough therapy designation and
orphan drug designation from the FDA.
Firdapse is currently being evaluated in
clinical trials for the treatment of MuSK-MG and SMA Type 3 and has
received Orphan Drug Designation from the FDA for
myasthenia gravis and CMS. Firdapse (amifampridine) 10 mg tablets
is the first and only approved drug in Europe for the
symptomatic treatment in adults with LEMS.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2018 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From May 2023 to May 2024